Civik Thomas 4

What Happened

• Civik Thomas, Interim Chief Executive Officer and director of Pyxis Oncology (PYXS), received a derivative equity award on February 3, 2026 covering 690,131 shares. The reported acquisition price is $0.00, indicating no cash was paid at grant.

Key Details

• Transaction date: 2026-02-03; Form 4 filed: 2026-02-05 (filed two days after the transaction).
• Award type: derivative grant (described in the filing as an option); acquisition price reported as $0.00.
• Vesting: the shares subject to the option vest in 12 equal monthly installments beginning on the grant date, subject to continued service as Interim CEO (per footnote).
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication in this filing of an immediate exercise or sale, tax withholding, 10b5-1 plan, or other special conditions beyond the vesting schedule.

Context

• This is a grant of derivative awards (an option) rather than an open-market purchase or sale. Such grants are commonly used to compensate and retain executives and align their interests with shareholders; they do not by themselves represent a cash purchase or sale of shares.